<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Eur Urol</journal-id>
        <journal-id journal-id-type="iso-abbrev">Eur. Urol.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>European urology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0302-2838</issn>
        <issn pub-type="epub">1873-7560</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC6339572</article-id>
        <article-id pub-id-type="pmcid-ver">PMC6339572.1</article-id>
        <article-id pub-id-type="pmcaid">6339572</article-id>
        <article-id pub-id-type="pmcaiid">6339572</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1508722</article-id>
        <article-id pub-id-type="pmid">30290956</article-id>
        <article-id pub-id-type="doi">10.1016/j.eururo.2018.09.002</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1508722</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1508722</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Pietzak</surname>
              <given-names initials="EJ">Eugene J.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
            <xref rid="CR1" ref-type="corresp">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zabor</surname>
              <given-names initials="EC">Emily C.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">b</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bagrodia</surname>
              <given-names initials="A">Aditya</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Armenia</surname>
              <given-names initials="J">Joshua</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hu</surname>
              <given-names initials="W">Wenhuo</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zehir</surname>
              <given-names initials="A">Ahmet</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Funt</surname>
              <given-names initials="S">Samuel</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Audenet</surname>
              <given-names initials="F">Francois</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Barron</surname>
              <given-names initials="D">David</given-names>
            </name>
            <xref ref-type="aff" rid="A5">e</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Maamouri</surname>
              <given-names initials="N">Noelia</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Li</surname>
              <given-names initials="Q">Qiang</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Teo</surname>
              <given-names initials="MY">Min Yuen</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Arcila</surname>
              <given-names initials="ME">Maria E.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dalbagni</surname>
              <given-names initials="G">Guido</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Herr</surname>
              <given-names initials="HW">Harry W.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bajorin</surname>
              <given-names initials="DF">Dean F.</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rosenberg</surname>
              <given-names initials="JE">Jonathan E.</given-names>
            </name>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Al-Ahmadie</surname>
              <given-names initials="H">Hikmat</given-names>
            </name>
            <xref ref-type="aff" rid="A6">f</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bochner</surname>
              <given-names initials="BH">Bernard H.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">a</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Iyer</surname>
              <given-names initials="G">Gopa</given-names>
            </name>
            <xref ref-type="aff" rid="A3">c</xref>
            <xref ref-type="aff" rid="A4">d</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>a</label>Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A2"><label>b</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A3"><label>c</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A4"><label>d</label>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A5"><label>e</label>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <aff id="A6"><label>f</label>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
        <author-notes>
          <fn fn-type="con" id="FN1">
            <p id="P1"><bold>Author contributions:</bold> Eugene J. Pietzak had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
            <p id="P2"><italic toggle="yes">Study concept and design</italic>: Pietzak, Al-Ahmadie, Bochner, Solit, Iyer.</p>
            <p id="P3"><italic toggle="yes">Acquisition of data</italic>: Pietzak, Bagrodia, Audenet, Funt, Barron, Maamouri, Li.</p>
            <p id="P4"><italic toggle="yes">Analysis and interpretation of data</italic>: Pietzak, Zabor, Bagrodia, Armenia, Hu, Zehir, Berger, Schultz, Teo, Dalbagni, Herr, Bajorin, Rosenberg, Al-Ahmadie, Bochner, Solit, Iyer.</p>
            <p id="P5"><italic toggle="yes">Drafting of the manuscript</italic>: Pietzak, Solit, Iyer.</p>
            <p id="P6"><italic toggle="yes">Critical revision of the manuscript for important intellectual content</italic>: All authors.</p>
            <p id="P7"><italic toggle="yes">Statistical analysis</italic>: Zabor.</p>
            <p id="P8"><italic toggle="yes">Obtaining funding</italic>: Pietzak, Bochner, Solit.</p>
            <p id="P9"><italic toggle="yes">Administrative, technical, or material support</italic>: Arcila, Berger, Schultz. <italic toggle="yes">Supervision</italic>: Pietzak, Iyer.</p>
            <p id="P10"><italic toggle="yes">Other</italic>: None.</p>
          </fn>
          <corresp id="CR1"><label>*</label>Corresponding author. Urology Service, Department of Surgery, Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York, NY 10065, USA. Tel. +1 646 422 4781; Fax: +1 212 988 0759. <email>pietzake@MSKCC.org</email> (E.J. Pietzak).</corresp>
          <fn fn-type="COI-statement" id="FN2">
            <p id="P44"><bold><italic toggle="yes">Financial disclosures:</italic></bold> Eugene J. Pietzak certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.</p>
            <p id="P45">Pietzak: Scientific Advisory Board: Merck. Berger: Consultant: Roche; Research Support: Illumina. Funt: Research Support: Genentech, AstraZeneca; Stock ownership: Kite Pharma, Urogen Pharma, Allogene Therapeutics, Kronos Bio. Bajorin: Honoraria from the speaker’s bureau of Merck; Consultant/advisory board: Merck, Pfizer, Bristol-Myers Squibb, Urogen, Genentech, Eli Lilly. Rosenberg: Stock and Other Ownership Interests: Merck, Illumina; Honoraria: UpToDate, Bristol-Myers Squibb, AstraZeneca, Medscape, Vindico, Peerview, Chugai Pharma; Consulting or Advisory Role: Lilly, Merck, Agensys, Roche/Genentech, Sanofi, AstraZeneca/MedImmune, Bristol-Myers Squibb, EMD Serono, Seattle Genetic, Bayer, Inovio Pharmaceuticals, BioClin Therapeutics, QED Therapeutic, Adicet Bio, Sensei Biotherapeutics; Patents, Royalties, Other Intellectual Property: Predictor of platinum sensitivity; Research Funding: Genentech, Oncogenex, Agensys, Mirati Therapeutics, Novartis, Viralytics, Genentech/Roche, Incyte, Seattle Genetics, Bayer; Travel, Accommodations, Expenses: Genentech/Roche, Bristol-Myers Squibb. Bochner: Chair of data safety monitoring committee: Genentech; Course Instructor: Olympus. Al-Ahmadie: Consultant: Bristol-Myers-Squibb, AstraZeneca, EMD Serono. Solit: Consultant for Pfizer, Loxo Oncology and Illumina. Iyer: Consultant: Bayer</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>02</day>
          <month>10</month>
          <year>2018</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <month>2</month>
          <year>2019</year>
        </pub-date>
        <volume>75</volume>
        <issue>2</issue>
        <issue-id pub-id-type="pmc-issue-id">327860</issue-id>
        <fpage>231</fpage>
        <lpage>239</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>13</day>
              <month>10</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>02</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>02</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-06-18 14:25:28.847">
              <day>18</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1508722.pdf"/>
        <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="editorial" journal-id="Transl Androl Urol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC6642961">
          <article-title>Biomarkers for platinum sensitivity in bladder cancer: are we there yet?</article-title>
          <volume>8</volume>
          <issue>Suppl 3</issue>
          <date>
            <month>7</month>
            <year>2019</year>
          </date>
          <fpage>S236</fpage>
          <lpage>S239</lpage>
          <source>Translational Andrology and Urology</source>
          <pub-id pub-id-type="pmcid">PMC6642961</pub-id>
          <pub-id pub-id-type="pmid">31392132</pub-id>
        </related-article>
        <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="editorial" journal-id="Transl Cancer Res" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC8797631">
          <article-title>Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?</article-title>
          <volume>8</volume>
          <issue>Suppl 2</issue>
          <date>
            <month>3</month>
            <year>2019</year>
          </date>
          <fpage>S176</fpage>
          <lpage>S179</lpage>
          <source>Translational Cancer Research</source>
          <pub-id pub-id-type="doi">10.21037/tcr.2019.01.05</pub-id>
          <pub-id pub-id-type="pmcid">PMC8797631</pub-id>
          <pub-id pub-id-type="pmid">35117093</pub-id>
        </related-article>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Background:</title>
            <p id="P11">Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC). It is unknown whether this treatment strategy is appropriate for patients who progress to MIBC after treatment for prior noninvasive disease (secondary MIBC).</p>
          </sec>
          <sec id="S2">
            <title>Objective:</title>
            <p id="P12">To determine whether clinical and genomic differences exist between primary and secondary MIBC treated with NAC and RC.</p>
          </sec>
          <sec id="S3">
            <title>Design, setting, and participants:</title>
            <p id="P13">Clinicopathologic outcomes were compared between 245 patients with clinical T2–4aN0M0-stage primary MIBC and 43 with secondary MIBC treated with NAC and RC at Memorial Sloan Kettering Cancer Center (MSKCC) from 2001 to 2015. Genomic differences were assessed in a retrospective cohort of 385 prechemotherapy specimens sequenced by whole-exome or targeted exon capture by the Cancer Genome Atlas or at MSKCC. Findings were confirmed in an independent validation cohort of 94 MIBC patients undergoing prospective targeted exon sequencing at MSKCC.</p>
          </sec>
          <sec id="S4">
            <title>Outcome measurements and statistical analysis:</title>
            <p id="P14">Pathologic response rates, recurrencefree survival (RFS), bladder cancer-specific survival (CSS), and overall survival (OS) were measured. Differences in somatic genomic alteration rates were compared using Fisher’s exact test and the Benjamini-Hochberg false discovery rate method.</p>
          </sec>
          <sec id="S5">
            <title>Results and limitations:</title>
            <p id="P15">Patients with secondary MIBC had lower pathologic response rates following NAC than those with primary MIBC (univariable: 26% vs 45%, multivariable: odds ratio = 0.4 [95% confidence interval = 0.18−0.84] <italic toggle="yes">p</italic> = 0.02) and significantly worse RFS, CSS, and OS. Patients with secondary MIBC treated with NAC had worse CSS compared with cystectomy alone (<italic toggle="yes">p</italic> = 0.002). In a separate genomic analysis, we detected significantly more likely deleterious somatic <italic toggle="yes">ERCC2</italic> missense mutations in primary MIBC tumors in both the discovery (10.9% [36/330] vs 1.8% [1/55], <italic toggle="yes">p</italic> = 0.04) and the validation (15.7% [12/70] vs 0% [0/24], <italic toggle="yes">p</italic> = 0.03) cohort.</p>
          </sec>
          <sec id="S6">
            <title>Conclusions:</title>
            <p id="P16">Patients with secondary MIBC treated with NAC had worse clinical outcomes than similarly treated patients with primary MIBC. <italic toggle="yes">ERCC2</italic> mutations predicted to result in increased cisplatin sensitivity were enriched in primary versus secondary MIBC. Prospective validation is still needed, but given the lack of clinical benefit with cisplatin-based NAC in patients with secondary MIBC, upfront RC or enrollment in clinical trials should be considered.</p>
          </sec>
          <sec id="S7">
            <title>Patient summary:</title>
            <p id="P17">A retrospective cohort study of patients with “primary” and “secondary” muscle-invasive bladder cancer (MIBC) treated with chemotherapy before surgical removal of the bladder identified lower response rates and shorter survival in patients with secondary MIBC. Tumor genetic sequencing of separate discovery and validation cohorts revealed that chemotherapy-sensitizing DNA damage repair gene mutations occur predominantly in primary MIBC tumors and may underlie the greater sensitivity of primary MIBC to chemotherapy. Prospective validation is still needed, but patients with secondary MIBC may derive greater benefit from upfront surgery or enrollment in clinical trials rather than from standard chemotherapy.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>Bladder cancer</kwd>
          <kwd>ERCC2</kwd>
          <kwd>Muscle-invasive bladder cancer</kwd>
          <kwd>Neoadjuvant chemotherapy</kwd>
          <kwd>Non–muscle-invasive bladder cancer</kwd>
          <kwd>Radical cystectomy</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
